Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Société Française de Greffe de Moëlle et de Thérapie Cellulaire

Gouill, Steven Le; Milpied, Noël; Buzyn, Agnès; Latour, Régis Peffault de; Vernant, Jean‐Paul; Mohty, Mohamad; Moles, Marie‐Pierre; Bouabdallah, Krimo; Bulabois, Claude‐Eric; Dupuis, Jehan; Rio, Bernard; Gratecos, N; Yakoub-Agha, Ibrahim; Attal, Michel; Tournilhac, Olivier; Decaudin, Didier; Bourhis, J.; Blaise, Didier; Volteau, Christelle; Michallet, Mauricette

doi:10.1200/jco.2007.14.1366

Cited by 276 publications

(225 citation statements)

References 25 publications

Supporting

Mentioning

205

Contrasting

Unclassified

Order By: Relevance

“…15,35,36 Similarly, Corradini et al 35 reported 17 patients with relapsed or refractory disease who underwent a reduced intensity allogeneic procedure. The authors found an impressive OS of 80% and PFS of 60% at 3 years.…”

Section: Allo-hsct For Ptclmentioning

confidence: 99%

See 1 more Smart Citation

Hematopoietic SCT for peripheral T-cell lymphoma

Gutiérrez

Caballero

Perez-Manga

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

Results of conventional chemotherapy for high-risk peripheral T-cell lymphoma (PTCL) are poor compared with those for their aggressive B-cell counterparts. We aim to review the current data on the use of hematopoietic SCT in these patients in both frontline and salvage settings. With respect to autologous SCT (ASCT), conclusions from retrospective studies are that ASCT in the salvage setting is as useful in PTCL as in aggressive B-cell lymphomas and also that consolidation in first complete response of high-risk patients has very good results when compared with conventional chemotherapy (with long-term PFS higher than 50%). From first frontline prospective clinical trials, it appears that ASCT is feasible and has a low TRM (o5%); consolidation in first complete response is associated with a very good outcome; around 25% of patients do not undergo ASCT due mainly to disease progression; new approaches aimed at increasing the number of chemosensitive patients should be found. Furthermore, 25-30% of patients deemed complete responders post transplant still relapse afterward. For all these mainly chemoresistant patients, there is preliminary evidence that allogeneic SCT (Allo-SCT) may produce a plateau in survival curves (with long-term PFS around 50%), which indicates a graft-versus-PTCL effect. For this reason, Allo-SCT procedures are the object of ongoing clinical trials.

show abstract

Section: Allo-hsct For Ptclmentioning

confidence: 99%

“…Recently, Le Gouill et al 36 and other French investigators have reported their retrospective experience in 77 patients with several subtypes of PTCL who underwent Allo-HSCT. In this series, most patients underwent a full myeloablative procedure and again the results were encouraging with a 57% 5-year OS and a corresponding 53% EFS.…”

Section: Allo-hsct For Ptclmentioning

confidence: 99%

Hematopoietic SCT for peripheral T-cell lymphoma

Gutiérrez

Caballero

Perez-Manga

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…[1][2][3] RIC regimens also have been investigated in patients with aggressive lymphomas: Most of those studies included various B-cell and T-cell histotypes, and the estimated 3-year PFS rates have been 15% to 20% in patients with chemoresistant disease and 45% to 55% in patients with chemosensitive disease. [4][5][6][7] Chemosensitivity is 1 of the most important prognostic factors affecting final outcomes in patients who receive myeloablative conditioning, and is also important for patients who receive RIC regimens. We recently demonstrated better overall survival (OS) and PFS in patients with lymphoma who underwent an allograft in complete remission compared with the survival of patients who underwent transplantation in partial remission or with refractory disease.…”

mentioning

confidence: 99%

Pretransplantation [18‐F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non‐Hodgkin lymphoma undergoing reduced‐intensity conditioning followed by allogeneic stem cell transplantation

Dodero

Crocchiolo

Miceli

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND:The use of positron emission tomography (PET) scanning in Hodgkin lymphoma (HL) and aggressive non-Hodgkin lymphoma (HG-NHL) has recognized prognostic value in patients who are receiving chemotherapy or undergoing autologous stem cell transplantation (SCT). In contrast, the role of PET before reduced-intensity conditioning (RIC) and followed by allogeneic SCT has not been investigated to date. METHODS: PET was used to assess 80 patients who had chemosensitive disease (34 patients with HG-NHL and 46 patients with HL) before they underwent allogeneic SCT: 42 patients had negative PET studies, and 38 patients had positive PET studies. Patients underwent allograft from matched related siblings (n ¼ 41) or alternative donors (n ¼ 39). RESULTS: At the time of the last follow-up, 48 patients were alive (60%), and 32 had died. The 3-year cumulative incidence of nonrecurrence mortality and disease recurrence was 17% and 40%, respectively. The cumulative incidence of disease recurrence was significantly lower in the PET-negative patients (25% vs 56%; P ¼ .007), but there was no significant difference between the patients with or without chronic graft-versus-host disease (P ¼ .400). The patients who had negative PET studies before undergoing allogenic SCT also had significantly better outcomes in terms of 3-year overall survival (76% vs 33%; P ¼ .001) and 3-year progression-free survival (73% vs 31%; P ¼ .001). On multivariate analysis, overall survival was influenced by PET status (hazard ratio [HR], 3.35), performance status (HR, 5.15), and type of donor (HR, 6.26 for haploidentical vs sibling; HR, 1.94 for matched unrelated donor vs sibling). CONCLUSIONS: The current results indicated that PET scanning appears to be an accurate tool for assessing prognosis in patients who are eligible for RIC allografting. Cancer 2010;116:5001-11.

show abstract

“…2 Allogenic SCT (allo-SCT) is increasingly used as an alternative strategy, based on a potent graft-versus-lymphoma effect (GvL). However, data from retrospective [3][4][5][6][7][8][9][10][11] and prospective non-randomized studies 12 are insufficient to recommend allo-SCT as first-line treatment. The European Bone Marrow Transplantation Society currently considers allo-SCT to be an option for selected patients with chemosensitive disease in first or second complete response (CR), if a sibling or unrelated HLA-matched donor is available (grade 2 recommendations).…”

Section: Introductionmentioning

confidence: 99%

“…Second, in most studies the survival curve stabilized after 12-18 months, suggesting a possible curative effect. 4 Third, chronic GvHD has been linked to a lower risk of relapse. 5 Finally, a negative impact on survival, due to a high relapse rate (70%), has been reported with T-cell-depleted grafts in primitive cutaneous T-cell lymphoma (TCL).…”

Section: Introductionmentioning

confidence: 99%

Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

Mamez

Lévy

Chevallier

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

Peripheral T-cell lymphoma carries a poor prognosis. To document a possible graft-versus-lymphoma effect in this setting, we evaluated the impact of immunomodulation in 63 patients with peripheral T-cell lymphoma who relapsed after allogeneic transplant in 27 SFGM-TC centers. Relapse occurred after a median of 2.8 months. Patients were then treated with nonimmunologic strategies (chemotherapy, radiotherapy) and/or immune modulation (donor lymphocyte infusions (DLI) and/or discontinuation of immunosuppressive therapy). Median overall survival (OS) after relapse was 6.1 months (DLI group: 23.6 months, non-DLI group: 3.6 months). Among the 14 patients who received DLI, 9 responded and 2 had stable disease. Among the remaining 49 patients, a complete response accompanied by extensive chronic GvHD was achieved in two patients after tapering of immunosuppressive drugs. Thirty patients received radio-chemotherapy, with an overall response rate of 50%. In multivariate analysis, chronic GvHD (odds ratio: 11.25 (2.68-48.21), P = 0.0009) and skin relapse (odds ratio: 4.15 (1.04-16.50), P = 0.043) were associated with a better response to treatment at relapse. In a time-dependent analysis, the only factor predictive of OS was the time from transplantation to relapse (hazards ratio: 0.33 (0.17-0.640), P = 0.0009). This large series provides encouraging evidence of a true GvL effect in this disease.

show abstract

Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Société Française de Greffe de Moëlle et de Thérapie Cellulaire

Abstract: We conclude that alloSCT is a potentially efficient therapy for NK/T lymphomas and is worth further investigation through prospective clinical trials.

Cited by 276 publications

References 25 publications

Hematopoietic SCT for peripheral T-cell lymphoma

Hematopoietic SCT for peripheral T-cell lymphoma

Pretransplantation [18‐F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non‐Hodgkin lymphoma undergoing reduced‐intensity conditioning followed by allogeneic stem cell transplantation

Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

Contact Info

Product

Resources

About